

Special Issue

Recent Advances in Pathogenesis, Diagnostics, and Therapies in Lung Diseases

Message from the Guest Editor

Lung diseases, affecting millions globally, present complex challenges due to their multifaceted genetic and environmental pathogenesis. Recent advancements, such as transcriptomics, epigenomics, and single-cell sequencing, have provided significant insights into their genetic underpinnings and pathobiology. This Special Issue invites contributions exploring the latest advances in lung disease pathogenesis, novel diagnostics, and therapies, with an emphasis on genetic aspects. We particularly welcome research featuring transcriptomics, epigenomics, single-cell sequencing, gene delivery, and immunotherapies. We anticipate your valuable submissions to highlight and further our understanding in this critical domain.

Guest Editor

Dr. Kong Chen

Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

Deadline for manuscript submissions

closed (25 January 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/174747

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))